{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T17:05:39Z","timestamp":1788627939284,"version":"build-2803163510"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["7.6518.24"],"award-info":[{"award-number":["7.6518.24"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005627","name":"Universit\u00e9 de Li\u00e8ge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005627","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fonds de la Recherche Scientifique - FNRS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02877-1","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T08:05:04Z","timestamp":1776931504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacological modulation of CXCL12\/CXCR4\/ACKR3 for brain disorders \u2013 an overview"],"prefix":"10.1186","volume":"24","author":[{"given":"Amandine","family":"Kuppens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Rogister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Neirinckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"issue":"1","key":"2877_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41392-020-00435-w","volume":"6","author":"D Yang","year":"2021","unstructured":"Yang D, et al. G protein-coupled receptors: structure- and function-based drug discovery. Signal Transduct Target Ther. 2021;6(1):7. https:\/\/doi.org\/10.1038\/s41392-020-00435-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"2877_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nrd.2017.178","volume":"16","author":"AS Hauser","year":"2017","unstructured":"Hauser AS, Attwood MM, Rask-Andersen M, Schi\u00f6th HB, Gloriam DE. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2017;16(12):829\u201342. https:\/\/doi.org\/10.1038\/nrd.2017.178.","journal-title":"Nat Rev Drug Discov"},{"key":"2877_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3390\/cells9020506","volume":"9","author":"S Azam","year":"2020","unstructured":"Azam S, et al. G-Protein-Coupled Receptors in CNS: A Potential Neurodegenerative Disorders and Associated. Cells. 2020;9:506.","journal-title":"Cells"},{"key":"2877_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1146\/annurev.immunol.18.1.217","volume":"18","author":"D Rossi","year":"2000","unstructured":"Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 2000;18:217\u201342. https:\/\/doi.org\/10.1146\/annurev.immunol.18.1.217.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"2877_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.113.007724","volume":"66","author":"F Bachelerie","year":"2014","unstructured":"Bachelerie F, et al. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2014;66(1):1\u201379. https:\/\/doi.org\/10.1124\/pr.113.007724.","journal-title":"Pharmacol Rev"},{"key":"2877_CR6","doi-asserted-by":"publisher","unstructured":"R\u00e9aux-Le Goazigo A, Van Steenwinckel J, Rost\u00e8ne W, M\u00e9lik Parsadaniantz S. Current status of chemokines in the adult CNS. Prog Neurobiol. 2013;104:67\u201392. https:\/\/doi.org\/10.1016\/j.pneurobio.2013.02.001.","DOI":"10.1016\/j.pneurobio.2013.02.001"},{"key":"2877_CR7","doi-asserted-by":"publisher","unstructured":"Janssens R, Struyf S, Proost P. Pathological roles of the homeostatic chemokine CXCL12., Cytokine Growth Factor Rev. 2018;44:51\u201368 https:\/\/doi.org\/10.1016\/j.cytogfr.2018.10.004.","DOI":"10.1016\/j.cytogfr.2018.10.004"},{"key":"2877_CR8","doi-asserted-by":"publisher","unstructured":"Tachibana K et al. Jun., The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract., Nature. 1998;393(6685):591\u2013594 https:\/\/doi.org\/10.1038\/31261.","DOI":"10.1038\/31261"},{"key":"2877_CR9","doi-asserted-by":"publisher","unstructured":"Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development., Nature. 1998;393(6685):595\u2013599. https:\/\/doi.org\/10.1038\/31269.","DOI":"10.1038\/31269"},{"key":"2877_CR10","doi-asserted-by":"publisher","unstructured":"Ma Q et al. Aug., Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice., Proc. Natl. Acad. Sci. U. S. A.1998;95(16):9448\u20139453. https:\/\/doi.org\/10.1073\/pnas.95.16.9448.","DOI":"10.1073\/pnas.95.16.9448"},{"issue":"4","key":"2877_CR11","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.mcn.2005.07.019","volume":"30","author":"V \u00d6demis","year":"2005","unstructured":"\u00d6demis V, et al. Mice deficient in the chemokine receptor CXCR4 exhibit impaired limb innervation and myogenesis. Mol Cell Neurosci. 2005;30(4):494\u2013505. https:\/\/doi.org\/10.1016\/j.mcn.2005.07.019.","journal-title":"Mol Cell Neurosci"},{"key":"2877_CR12","doi-asserted-by":"publisher","unstructured":"Nagasawa T et al. Aug., Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF\/SDF-1., Nature. 1996;382(6592):635\u2013638 https:\/\/doi.org\/10.1038\/382635a0.","DOI":"10.1038\/382635a0"},{"key":"2877_CR13","doi-asserted-by":"publisher","unstructured":"Sierro F et al. Sep., Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12\/SDF-1 receptor, CXCR7. Proc. Natl. Acad. Sci. U. S. A. 2007;104(37):14759\u201314764. https:\/\/doi.org\/10.1073\/pnas.0702229104.","DOI":"10.1073\/pnas.0702229104"},{"key":"2877_CR14","doi-asserted-by":"publisher","unstructured":"Gerrits H, et al. Early postnatal lethality and cardiovascular defects in CXCR7-deficient mice. Genesis. 2008;46(5):235\u201345. https:\/\/doi.org\/10.1002\/dvg.20387.","DOI":"10.1002\/dvg.20387"},{"key":"2877_CR15","doi-asserted-by":"publisher","unstructured":"Shirozu M, et al. Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics. 1995;28(3):495\u2013500. https:\/\/doi.org\/10.1006\/geno.1995.1180.","DOI":"10.1006\/geno.1995.1180"},{"key":"2877_CR16","doi-asserted-by":"publisher","unstructured":"Chen K, Bao Z, Tang P, Gong W, Yoshimura T, Wang JM. Chemokines in homeostasis and diseases. Cell. Mol. Immunol. 2018;15(4)324\u2013334. https:\/\/doi.org\/10.1038\/cmi.2017.134.","DOI":"10.1038\/cmi.2017.134"},{"key":"2877_CR17","doi-asserted-by":"publisher","unstructured":"Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches., Immunity. 2006;25(6):977\u2013988. https:\/\/doi.org\/10.1016\/j.immuni.2006.10.016.","DOI":"10.1016\/j.immuni.2006.10.016"},{"issue":"3","key":"2877_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4161\/cam.3.3.8260","volume":"3","author":"M Janowski","year":"2009","unstructured":"Janowski M. Functional diversity of SDF-1 splicing variants. Cell Adh Migr. 2009;3(3):243\u20139. https:\/\/doi.org\/10.4161\/cam.3.3.8260.","journal-title":"Cell Adh Migr"},{"key":"2877_CR19","doi-asserted-by":"publisher","unstructured":"Righetti A, Giulietti M, \u0160abanovi\u0107 B, Occhipinti G, Principato G, Piva F. CXCL12 and Its Isoforms: Different Roles in Pancreatic Cancer? J. Oncol. 2019;2019:1-13. https:\/\/doi.org\/10.1155\/2019\/9681698.","DOI":"10.1155\/2019\/9681698"},{"key":"2877_CR20","doi-asserted-by":"publisher","first-page":"1133394","DOI":"10.3389\/fimmu.2023.1133394","volume":"14","author":"M Szpakowska","year":"2023","unstructured":"Szpakowska M, et al. New pairings and deorphanization among the atypical chemokine receptor family - physiological and clinical relevance. Front Immunol. 2023;14:1133394. https:\/\/doi.org\/10.3389\/fimmu.2023.1133394.","journal-title":"Front Immunol"},{"key":"2877_CR21","doi-asserted-by":"crossref","unstructured":"Loetscher M, Geiser T, O\u2019Reilly T, Zwahlen R, Baggiolini M, Moser B. Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J Biol Chem. 1994;269(1):232\u20137.","DOI":"10.1016\/S0021-9258(17)42339-8"},{"key":"2877_CR22","doi-asserted-by":"publisher","unstructured":"Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272(5263):872\u20137. https:\/\/doi.org\/10.1126\/science.272.5263.872.","DOI":"10.1126\/science.272.5263.872"},{"key":"2877_CR23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3389\/fimmu.2015.00429","volume":"6","author":"L Pawig","year":"2015","unstructured":"Pawig L, Klasen C, Weber C, Bernhagen J, Noels H. Diversity and Inter-Connections in the CXCR4 Chemokine Receptor\/Ligand Family: Molecular Perspectives. Front Immunol. 2015;6:429. https:\/\/doi.org\/10.3389\/fimmu.2015.00429.","journal-title":"Front Immunol"},{"key":"2877_CR24","doi-asserted-by":"publisher","unstructured":"Feng Z, Dubyak GR, Lederman MM, Weinberg A. Cutting edge: human beta defensin 3\u2013a novel antagonist of the HIV-1 coreceptor CXCR4. J. Immunol. 2006;177(2)782\u2013786. https:\/\/doi.org\/10.4049\/jimmunol.177.2.782.","DOI":"10.4049\/jimmunol.177.2.782"},{"key":"2877_CR25","doi-asserted-by":"publisher","unstructured":"Bernhagen J, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007;13(5):587\u201396. https:\/\/doi.org\/10.1038\/nm1567.","DOI":"10.1038\/nm1567"},{"key":"2877_CR26","doi-asserted-by":"publisher","unstructured":"Saini V et al. Sep., The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-1\u03b1 function through distinct receptor interactions. J. Biol. Chem. 2011;286(38):33466\u201333477. https:\/\/doi.org\/10.1074\/jbc.M111.233742.","DOI":"10.1074\/jbc.M111.233742"},{"key":"2877_CR27","doi-asserted-by":"publisher","unstructured":"Pello OM et al. Feb., Ligand stabilization of CXCR4\/delta-opioid receptor heterodimers reveals a mechanism for immune response regulation. Eur. J. Immunol. 2008;38(2):537\u2013549. https:\/\/doi.org\/10.1002\/eji.200737630.","DOI":"10.1002\/eji.200737630"},{"key":"2877_CR28","doi-asserted-by":"publisher","unstructured":"Coke CJ, et al. Simultaneous Activation of Induced Heterodimerization between CXCR4 Chemokine Receptor and Cannabinoid Receptor 2 (CB2) Reveals a Mechanism for Regulation of Tumor Progression. J Biol Chem. 2016;291:9991\u201310005. https:\/\/doi.org\/10.1074\/jbc.M115.712661.","DOI":"10.1074\/jbc.M115.712661"},{"key":"2877_CR29","doi-asserted-by":"publisher","unstructured":"Libert F, Parmentier M, Lefort A, Dumont JE, Vassart G. Complete nucleotide sequence of a putative G protein coupled receptor: RDC1. Nucleic Acids Res. 1990;18(7):1917. https:\/\/doi.org\/10.1093\/nar\/18.7.1917.","DOI":"10.1093\/nar\/18.7.1917"},{"key":"2877_CR30","doi-asserted-by":"publisher","unstructured":"Heesen M, Berman MA, Charest A, Housman D, Gerard C, Dorf ME. Cloning and chromosomal mapping of an orphan chemokine receptor: mouse RDC1., Immunogenetics. 1998;47(5):364\u2013370. https:\/\/doi.org\/10.1007\/s002510050371.","DOI":"10.1007\/s002510050371"},{"key":"2877_CR31","doi-asserted-by":"publisher","unstructured":"Balabanian K et al. Oct., The chemokine SDF-1\/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J. Biol. Chem. 2005;280(42):35760\u201335766. https:\/\/doi.org\/10.1074\/jbc.M508234200.","DOI":"10.1074\/jbc.M508234200"},{"key":"2877_CR32","doi-asserted-by":"publisher","unstructured":"Burns JM et al. Sep., A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 2006;203(9):2201\u20132213. https:\/\/doi.org\/10.1084\/jem.20052144.","DOI":"10.1084\/jem.20052144"},{"key":"2877_CR33","doi-asserted-by":"publisher","unstructured":"Szpakowska M, et al. Human herpesvirus 8-encoded chemokine vCCL2\/vMIP-II is an agonist of the atypical chemokine receptor ACKR3\/CXCR7. Biochem Pharmacol. 2016;114:14\u201321. https:\/\/doi.org\/10.1016\/j.bcp.2016.05.012.","DOI":"10.1016\/j.bcp.2016.05.012"},{"key":"2877_CR34","doi-asserted-by":"publisher","unstructured":"Meyrath M, et al. The atypical chemokine receptor ACKR3\/CXCR7 is a broad-spectrum scavenger for opioid peptides. Nat Commun. 2020;11(1):3033. https:\/\/doi.org\/10.1038\/s41467-020-16664-0.","DOI":"10.1038\/s41467-020-16664-0"},{"key":"2877_CR35","doi-asserted-by":"publisher","unstructured":"Meyrath M, et al. Proadrenomedullin N-Terminal 20 Peptides (PAMPs) Are Agonists of the Chemokine Scavenger Receptor ACKR3\/CXCR7. ACS Pharmacol Transl Sci. 2021;4(2):813\u201323. https:\/\/doi.org\/10.1021\/acsptsci.1c00006.","DOI":"10.1021\/acsptsci.1c00006"},{"key":"2877_CR36","doi-asserted-by":"publisher","unstructured":"Szpakowska M et al. Mar., Inclusion of ACKR5 in the systematic nomenclature of atypical chemokine receptors. Nature reviews. Immunology. 2025;25(3):225\u2013226. https:\/\/doi.org\/10.1038\/s41577-025-01135-8.","DOI":"10.1038\/s41577-025-01135-8"},{"key":"2877_CR37","doi-asserted-by":"publisher","unstructured":"Samus M, Rot A. Atypical chemokine receptors in cancer. Cytokine. 2024;176(2023):156504. https:\/\/doi.org\/10.1016\/j.cyto.2024.156504","DOI":"10.1016\/j.cyto.2024.156504"},{"key":"2877_CR38","doi-asserted-by":"publisher","unstructured":"Rajagopal S et al. \u03b2-Arrestin- But not G protein-mediated signaling by the \u2018decoy\u2019 receptor CXCR7, Proc. Natl. Acad. Sci. U. S. A. 2010;107(2):628\u2013632. https:\/\/doi.org\/10.1073\/pnas.0912852107.","DOI":"10.1073\/pnas.0912852107"},{"issue":"3","key":"2877_CR39","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/glia.22271","volume":"60","author":"V \u00d6demis","year":"2012","unstructured":"\u00d6demis V, et al. The presumed atypical chemokine receptor CXCR7 signals through Gi\/o proteins in primary rodent astrocytes and human glioma cells. Glia. 2012;60(3):372\u201381. https:\/\/doi.org\/10.1002\/glia.22271.","journal-title":"Glia"},{"key":"2877_CR40","doi-asserted-by":"publisher","unstructured":"Yen Y-C, et al. Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias. Sci Adv. 2022;8(28):eabn8063. https:\/\/doi.org\/10.1126\/sciadv.abn8063.","DOI":"10.1126\/sciadv.abn8063"},{"key":"2877_CR41","doi-asserted-by":"publisher","unstructured":"Graham GJ, Locati M, Mantovani A, Rot A, Thelen M. The biochemistry and biology of the atypical chemokine receptors. Immunol Lett. 2012;145:1\u20132. https:\/\/doi.org\/10.1016\/j.imlet.2012.04.004.","DOI":"10.1016\/j.imlet.2012.04.004"},{"key":"2877_CR42","doi-asserted-by":"publisher","unstructured":"Gutjahr JC, et al. The dimeric form of CXCL12 binds to atypical chemokine receptor 1. Sci Signal. 2021;14(696). https:\/\/doi.org\/10.1126\/scisignal.abc9012.","DOI":"10.1126\/scisignal.abc9012"},{"key":"2877_CR43","doi-asserted-by":"publisher","unstructured":"Chevign\u00e9 A, Legler DF, Rot A, Sozzani S, Szpakowska M, Thelen M. International Union of Basic and Clinical Pharmacology. CXVIII. Update on the nomenclature for atypical chemokine receptors, including ACKR5. Pharmacol Rev. 2025;77(1):100012. https:\/\/doi.org\/10.1124\/pharmrev.124.001361.","DOI":"10.1124\/pharmrev.124.001361"},{"key":"2877_CR44","doi-asserted-by":"publisher","unstructured":"Le Mercier A et al. Apr., GPR182 is an endothelium-specific atypical chemokine receptor that maintains hematopoietic stem cell homeostasis. Proc. Natl. Acad. Sci. U. S. A. 2021;118(17). https:\/\/doi.org\/10.1073\/pnas.2021596118.","DOI":"10.1073\/pnas.2021596118"},{"key":"2877_CR45","doi-asserted-by":"publisher","unstructured":"Bao S, et al. CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment. J Cancer Res Clin Oncol. 2023;149(10):7945\u201368. https:\/\/doi.org\/10.1007\/s00432-022-04444-w.","DOI":"10.1007\/s00432-022-04444-w"},{"key":"2877_CR46","doi-asserted-by":"publisher","unstructured":"Pozzobon T, Goldoni G, Viola A, Molon B. CXCR4 signaling in health and disease. Immunol Lett. 2016;177:6\u201315. https:\/\/doi.org\/10.1016\/j.imlet.2016.06.006.","DOI":"10.1016\/j.imlet.2016.06.006"},{"key":"2877_CR47","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Cuesta EM, Santiago CA, Vallejo-D\u00edaz J, Juarranz Y, Rodr\u00edguez-Frade JM, Mellado M. The Role of the CXCL12\/CXCR4\/ACKR3 Axis in Autoimmune Diseases, Front. Endocrinol. (Lausanne). 2019;10:1\u201316. https:\/\/doi.org\/10.3389\/fendo.2019.00585.","DOI":"10.3389\/fendo.2019.00585"},{"key":"2877_CR48","doi-asserted-by":"publisher","first-page":"574667","DOI":"10.3389\/fphar.2020.574667","volume":"11","author":"Y Shi","year":"2020","unstructured":"Shi Y, Riese DJ 2, Shen J. The Role of the CXCL12\/CXCR4\/CXCR7 Chemokine Axis in Cancer. Front Pharmacol. 2020;11:574667. https:\/\/doi.org\/10.3389\/fphar.2020.574667.","journal-title":"Front Pharmacol"},{"key":"2877_CR49","doi-asserted-by":"publisher","unstructured":"Hicks C, et al. ACKR3 Proximity Labeling Identifies Novel G protein- and \u03b2-arrestin-independent GPCR Interacting Proteins. bioRxiv Prepr Serv Biol. 2024. https:\/\/doi.org\/10.1101\/2024.01.27.577545.","DOI":"10.1101\/2024.01.27.577545"},{"key":"2877_CR50","doi-asserted-by":"publisher","unstructured":"Luker KE, Steele JM, Mihalko LA, Ray P, Luker GD. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Oncogene. 2010;29(32):4599\u20134610. https:\/\/doi.org\/10.1038\/onc.2010.212.","DOI":"10.1038\/onc.2010.212"},{"key":"2877_CR51","doi-asserted-by":"crossref","unstructured":"Vila-Coro AJ, Rodr\u00edguez-Frade JM, Mart\u00edn A, De Ana MC, Moreno-Ort\u00edz C, Mart\u00ednez-A, Mellado M. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK\/STAT pathway. FASEB J Off Publ Fed Am Soc Exp Biol. 1999;13(13):1699\u2013710.","DOI":"10.1096\/fasebj.13.13.1699"},{"key":"2877_CR52","doi-asserted-by":"publisher","unstructured":"Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood. 2009;113(24):6085\u20136093. https:\/\/doi.org\/10.1182\/blood-2008-12-196618.","DOI":"10.1182\/blood-2008-12-196618"},{"key":"2877_CR53","doi-asserted-by":"publisher","unstructured":"Sohy D et al. Nov., Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of \u2018selective\u2019 antagonists. J. Biol. Chem. 2009;284(45):31270\u201331279. https:\/\/doi.org\/10.1074\/jbc.M109.054809.","DOI":"10.1074\/jbc.M109.054809"},{"key":"2877_CR54","doi-asserted-by":"publisher","unstructured":"Watts AO et al. Apr., Identification and profiling of CXCR3-CXCR4 chemokine receptor heteromer complexes. Br. J. Pharmacol. 2013;168(7):1662\u20131674. https:\/\/doi.org\/10.1111\/bph.12064.","DOI":"10.1111\/bph.12064"},{"key":"2877_CR55","doi-asserted-by":"publisher","unstructured":"Liang J et al. Apr., The \u03b22-adrenergic receptor associates with CXCR4 multimers in human cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2024;121(14):e2304897121. https:\/\/doi.org\/10.1073\/pnas.2304897121.","DOI":"10.1073\/pnas.2304897121"},{"key":"2877_CR56","doi-asserted-by":"publisher","unstructured":"Stumm R, Kolodziej A, Schulz S, Kohtz JD, H\u00f6llt V. Patterns of SDF-1alpha and SDF-1gamma mRNAs, migration pathways, and phenotypes of CXCR4-expressing neurons in the developing rat telencephalon. J Comp Neurol. 2007;502(3):382\u201399. https:\/\/doi.org\/10.1002\/cne.21336.","DOI":"10.1002\/cne.21336"},{"key":"2877_CR57","doi-asserted-by":"publisher","unstructured":"Dziembowska M, Tham TN, Lau P, Vitry S, Lazarini F, Dubois-Dalcq M. A role for CXCR4 signaling in survival and migration of neural and oligodendrocyte precursors. Glia. 2005;50(3):258\u201369. https:\/\/doi.org\/10.1002\/glia.20170.","DOI":"10.1002\/glia.20170"},{"key":"2877_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000096210","volume":"29","author":"O Berger","year":"2007","unstructured":"Berger O, Li G, Han S-M, Paredes M, Pleasure SJ. Expression of SDF-1 and CXCR4 during reorganization of the postnatal dentate gyrus. Dev Neurosci. 2007;29:1\u20132. https:\/\/doi.org\/10.1159\/000096210.","journal-title":"Dev Neurosci"},{"issue":"6","key":"2877_CR59","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.it.2004.04.002","volume":"25","author":"RS Klein","year":"2004","unstructured":"Klein RS, Rubin JB. Immune and nervous system CXCL12 and CXCR4: parallel roles in patterning and plasticity. Trends Immunol. 2004;25(6):306\u201314. https:\/\/doi.org\/10.1016\/j.it.2004.04.002.","journal-title":"Trends Immunol"},{"key":"2877_CR60","doi-asserted-by":"publisher","unstructured":"Li M, Ransohoff RM. Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog Neurobiol. 2008;84(2):116\u201331. https:\/\/doi.org\/10.1016\/j.pneurobio.2007.11.003.","DOI":"10.1016\/j.pneurobio.2007.11.003"},{"key":"2877_CR61","doi-asserted-by":"publisher","unstructured":"Zhu B et al. Nov., CXCL12 enhances human neural progenitor cell survival through a CXCR7- and CXCR4-mediated endocytotic signaling pathway. Stem Cells. 2012;30(11):2571\u20132583. https:\/\/doi.org\/10.1002\/stem.1239.","DOI":"10.1002\/stem.1239"},{"key":"2877_CR62","doi-asserted-by":"publisher","unstructured":"Trousse F, et al. Knockdown of the CXCL12\/CXCR7 chemokine pathway results in learning deficits and neural progenitor maturation impairment in mice. Brain Behav Immun. 2019;80:697\u2013710. https:\/\/doi.org\/10.1016\/j.bbi.2019.05.019.","DOI":"10.1016\/j.bbi.2019.05.019"},{"key":"2877_CR63","doi-asserted-by":"publisher","unstructured":"Lindsay HG, Hendrix CJ, Gonzalez Murcia JD, Haynie C, Weber KS. The Role of Atypical Chemokine Receptors in Neuroinflammation and Neurodegenerative Disorders. Int J Mol Sci. 2023;24(22). https:\/\/doi.org\/10.3390\/ijms242216493.","DOI":"10.3390\/ijms242216493"},{"key":"2877_CR64","doi-asserted-by":"publisher","unstructured":"Banisadr G, Podojil JR, Miller SD, Miller RJ. Pattern of CXCR7 Gene Expression in Mouse Brain Under Normal and Inflammatory Conditions., J. neuroimmune Pharmacol. Off. J. Soc. NeuroImmune Pharmacol. 2016;11(1):26\u201335. https:\/\/doi.org\/10.1007\/s11481-015-9616-y.","DOI":"10.1007\/s11481-015-9616-y"},{"key":"2877_CR65","doi-asserted-by":"publisher","unstructured":"Ehrlich AT, et al. Ackr3-Venus knock-in mouse lights up brain vasculature. Mol Brain. 2021;14(1):151. https:\/\/doi.org\/10.1186\/s13041-021-00862-y.","DOI":"10.1186\/s13041-021-00862-y"},{"key":"2877_CR66","doi-asserted-by":"publisher","unstructured":"Fumagalli A, et al. The atypical chemokine receptor 3 interacts with Connexin 43 inhibiting astrocytic gap junctional intercellular communication. Nat Commun. 2020;11(1):4855. https:\/\/doi.org\/10.1038\/s41467-020-18634-y.","DOI":"10.1038\/s41467-020-18634-y"},{"key":"2877_CR67","doi-asserted-by":"publisher","unstructured":"Yan J et al. Role of Cx43 and ACKR3 in Modulating Astrocytic Response and Neuronal Survival Post-Subarachnoid Hemorrhage, Glia. 2025;73(8):1565\u20131588. https:\/\/doi.org\/10.1002\/glia.70008.","DOI":"10.1002\/glia.70008"},{"key":"2877_CR68","doi-asserted-by":"publisher","unstructured":"Shyu W-C et al. Feb., Stromal cell-derived factor-1 alpha promotes neuroprotection, angiogenesis, and mobilization\/homing of bone marrow-derived cells in stroke rats. J. Pharmacol. Exp. Ther. 2008;324(2):834\u2013849. https:\/\/doi.org\/10.1124\/jpet.107.127746.","DOI":"10.1124\/jpet.107.127746"},{"key":"2877_CR69","doi-asserted-by":"publisher","unstructured":"Chu T, Shields LBE, Zhang YP, Feng S-Q, Shields CB, Cai J. CXCL12\/CXCR4\/CXCR7 Chemokine Axis in the Central Nervous System: Therapeutic Targets for Remyelination in Demyelinating Diseases., Neurosci. a Rev. J. bringing Neurobiol. Neurol. psychiatry. 2017;23(6):627\u2013648. https:\/\/doi.org\/10.1177\/1073858416685690.","DOI":"10.1177\/1073858416685690"},{"issue":"11","key":"2877_CR70","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s00125-009-1493-6","volume":"52","author":"SG Sayyed","year":"2009","unstructured":"Sayyed SG, et al. Podocytes produce homeostatic chemokine stromal cell-derived factor-1\/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia. 2009;52(11):2445\u201354. https:\/\/doi.org\/10.1007\/s00125-009-1493-6.","journal-title":"Diabetologia"},{"key":"2877_CR71","doi-asserted-by":"publisher","unstructured":"D. C. E, et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother. 1994;38(3):668\u201374. https:\/\/doi.org\/10.1128\/aac.38.4.668.","DOI":"10.1128\/aac.38.4.668"},{"key":"2877_CR72","doi-asserted-by":"publisher","unstructured":"Skerlj RT, et al. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem. 2010;53(8):3376\u201388. https:\/\/doi.org\/10.1021\/jm100073m.","DOI":"10.1021\/jm100073m"},{"key":"2877_CR73","doi-asserted-by":"publisher","unstructured":"Tripathi R, Kumar P. Preliminary study to identify CXCR4 inhibitors as potential therapeutic agents for Alzheimer\u2019s and Parkinson\u2019s diseases. Integr Biol (Camb). 2023;15. https:\/\/doi.org\/10.1093\/intbio\/zyad012.","DOI":"10.1093\/intbio\/zyad012"},{"key":"2877_CR74","doi-asserted-by":"publisher","unstructured":"Luo Z, Wang B, Chen Y, Liu H, Shi L. Novel CXCR4 Inhibitor CPZ1344 inhibits the proliferation, migration and angiogenesis of glioblastoma. Pathol Oncol Res. 2020;26(4):2597\u2013604. https:\/\/doi.org\/10.1007\/s12253-020-00827-x.","DOI":"10.1007\/s12253-020-00827-x"},{"key":"2877_CR75","doi-asserted-by":"publisher","unstructured":"Gravina GL, et al. The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2017;39(6):1010428317695528. https:\/\/doi.org\/10.1177\/1010428317695528.","DOI":"10.1177\/1010428317695528"},{"key":"2877_CR76","doi-asserted-by":"publisher","unstructured":"Gravina GL, et al. The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma. J Hematol Oncol. 2017;10(1). https:\/\/doi.org\/10.1186\/s13045-016-0377-8.","DOI":"10.1186\/s13045-016-0377-8"},{"issue":"9","key":"2877_CR77","doi-asserted-by":"publisher","first-page":"e74548","DOI":"10.1371\/journal.pone.0074548","volume":"8","author":"L Portella","year":"2013","unstructured":"Portella L, et al. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PLoS ONE. 2013;8(9):e74548. https:\/\/doi.org\/10.1371\/journal.pone.0074548.","journal-title":"PLoS ONE"},{"issue":"23","key":"2877_CR78","doi-asserted-by":"publisher","first-page":"6996","DOI":"10.1093\/emboj\/16.23.6996","volume":"16","author":"MP Crump","year":"1997","unstructured":"Crump MP, et al. Solution structure and basis for functional activity of stromal cell-derived factor\u20101; dissociation of CXCR4 activation from binding and inhibition of HIV\u20101. EMBO J. 1997;16(23):6996\u20137007. https:\/\/doi.org\/10.1093\/emboj\/16.23.6996.","journal-title":"EMBO J"},{"key":"2877_CR79","doi-asserted-by":"publisher","unstructured":"Richard-Bildstein S, et al. Discovery of the potent, selective, orally available CXCR7 antagonist ACT-1004-1239. J Med Chem. 2020;63(24):15864\u201382. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01588.","DOI":"10.1021\/acs.jmedchem.0c01588"},{"key":"2877_CR80","doi-asserted-by":"publisher","unstructured":"Zabel BA, et al. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol. 2009;183(5):3204\u201311. https:\/\/doi.org\/10.4049\/jimmunol.0900269.","DOI":"10.4049\/jimmunol.0900269"},{"key":"2877_CR81","doi-asserted-by":"publisher","unstructured":"Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol. 2009;75(5):1240\u20137. https:\/\/doi.org\/10.1124\/mol.108.053389.","DOI":"10.1124\/mol.108.053389"},{"key":"2877_CR82","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ejmech.2012.02.041","volume":"51","author":"M Wijtmans","year":"2012","unstructured":"Wijtmans M, et al. Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists. Eur J Med Chem. 2012;51:184\u201392. https:\/\/doi.org\/10.1016\/j.ejmech.2012.02.041.","journal-title":"Eur J Med Chem"},{"key":"2877_CR83","doi-asserted-by":"publisher","unstructured":"Salazar N, et al. A Chimeric Antibody against ACKR3\/CXCR7 in Combination with TMZ Activates Immune Responses and Extends Survival in Mouse GBM Models. Mol Ther. 2018;26(5):1354\u201365. https:\/\/doi.org\/10.1016\/j.ymthe.2018.02.030.","DOI":"10.1016\/j.ymthe.2018.02.030"},{"key":"2877_CR84","doi-asserted-by":"publisher","first-page":"105010","DOI":"10.1016\/j.phrs.2020.105010","volume":"159","author":"J Wang","year":"2020","unstructured":"Wang J, Tannous BA, Poznansky MC, Chen H. CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent. Pharmacol Res. 2020;159:105010. https:\/\/doi.org\/10.1016\/j.phrs.2020.105010.","journal-title":"Pharmacol Res"},{"key":"2877_CR85","doi-asserted-by":"publisher","unstructured":"McDermott DH et al. Jan., Plerixafor for the Treatment of WHIM Syndrome. N. Engl. J. Med. 2019;380(2):163\u2013170. https:\/\/doi.org\/10.1056\/NEJMoa1808575.","DOI":"10.1056\/NEJMoa1808575"},{"key":"2877_CR86","doi-asserted-by":"publisher","unstructured":"Pantin J, et al. Effect of high-dose plerixafor on CD34(+) cell mobilization in healthy stem cell donors: results of a randomized crossover trial. Haematologica. 2017;102(3):600\u20139. https:\/\/doi.org\/10.3324\/haematol.2016.147132.","DOI":"10.3324\/haematol.2016.147132"},{"key":"2877_CR87","doi-asserted-by":"publisher","unstructured":"Badolato R et al. Jul., A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome. Blood. 2024;144(1):35\u201345. https:\/\/doi.org\/10.1182\/blood.2023022658.","DOI":"10.1182\/blood.2023022658"},{"key":"2877_CR88","doi-asserted-by":"publisher","unstructured":"Hoy SM. Mavorixafor: First Approval. Drugs. 2024;84(8):969\u201375. https:\/\/doi.org\/10.1007\/s40265-024-02063-y.","DOI":"10.1007\/s40265-024-02063-y"},{"key":"2877_CR89","doi-asserted-by":"publisher","unstructured":"J\u00f8rgensen AS, et al. Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization. Commun Biol. 2021;4(1):569. https:\/\/doi.org\/10.1038\/s42003-021-02070-9.","DOI":"10.1038\/s42003-021-02070-9"},{"key":"2877_CR90","doi-asserted-by":"publisher","unstructured":"Cruz-Orengo L, Chen Y-J, Kim JH, Dorsey D, Song S-K, Klein RS. CXCR7 antagonism prevents axonal injury during experimental autoimmune encephalomyelitis as revealed by in vivo axial diffusivity. J Neuroinflammation. 2011;8:170. https:\/\/doi.org\/10.1186\/1742-2094-8-170.","DOI":"10.1186\/1742-2094-8-170"},{"key":"2877_CR91","doi-asserted-by":"publisher","first-page":"112363","DOI":"10.1016\/j.biopha.2021.112363","volume":"144","author":"C Huynh","year":"2021","unstructured":"Huynh C, et al. Target engagement of the first-in-class CXCR7 antagonist ACT-1004-1239 following multiple-dose administration in mice and humans. Biomed Pharmacother. 2021;144:112363. https:\/\/doi.org\/10.1016\/j.biopha.2021.112363. October.","journal-title":"Biomed Pharmacother"},{"key":"2877_CR92","doi-asserted-by":"publisher","unstructured":"Vater A et al. Jul., Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12. Clin. Pharmacol. Ther. 2013;94(1):150\u2013157. https:\/\/doi.org\/10.1038\/clpt.2013.58.","DOI":"10.1038\/clpt.2013.58"},{"issue":"6640","key":"2877_CR93","doi-asserted-by":"publisher","first-page":"eabo7649","DOI":"10.1126\/science.abo7649","volume":"380","author":"G Castellani","year":"2023","unstructured":"Castellani G, Croese T, Ramos JMP, Schwartz M. Transforming the understanding of brain immunity. Sci (80-). 2023;380(6640):eabo7649. https:\/\/doi.org\/10.1126\/science.abo7649.","journal-title":"Sci (80-)"},{"key":"2877_CR94","doi-asserted-by":"publisher","first-page":"100932","DOI":"10.1016\/j.bbih.2024.100932","volume":"43","author":"R Sarallah","year":"2025","unstructured":"Sarallah R, Jahani S, Soltani Khaboushan A, Moaveni AK, Amiri M, Majidi Zolbin M. The role of CXCL12\/CXCR4\/CXCR7 axis in cognitive impairment associated with neurodegenerative diseases. Brain Behav Immun - Heal. 2025;43:100932. https:\/\/doi.org\/10.1016\/j.bbih.2024.100932.","journal-title":"Brain Behav Immun - Heal"},{"key":"2877_CR95","doi-asserted-by":"publisher","unstructured":"Constantinescu CS, Farooqi N, O\u2019Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol. 2011;164(4):1079\u2013106. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01302.x.","DOI":"10.1111\/j.1476-5381.2011.01302.x"},{"key":"2877_CR96","doi-asserted-by":"publisher","unstructured":"McCandless EE, Wang Q, Woerner BM, Harper JM, Klein RS. CXCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis. J. Immunol. 2006;177(11):8053\u20138064. https:\/\/doi.org\/10.4049\/jimmunol.177.11.8053.","DOI":"10.4049\/jimmunol.177.11.8053"},{"key":"2877_CR97","doi-asserted-by":"publisher","unstructured":"Patel JR, McCandless EE, Dorsey D, Klein RS. CXCR4 promotes differentiation of oligodendrocyte progenitors and remyelination. Proc. Natl. Acad. Sci. U. S. A. 2010;107(24):11062\u201311067. https:\/\/doi.org\/10.1073\/pnas.1006301107.","DOI":"10.1073\/pnas.1006301107"},{"key":"2877_CR98","doi-asserted-by":"publisher","unstructured":"Cruz-Orengo L et al. Feb., CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity., J. Exp. Med. 2011;208(2):327\u2013339. https:\/\/doi.org\/10.1084\/jem.20102010.","DOI":"10.1084\/jem.20102010"},{"key":"2877_CR99","doi-asserted-by":"publisher","unstructured":"Williams JL, Patel JR, Daniels BP, Klein RS. Targeting CXCR7\/ACKR3 as a therapeutic strategy to promote remyelination in the adult central nervous system. J Exp Med. 2014;211(5):791\u20139. https:\/\/doi.org\/10.1084\/jem.20131224.","DOI":"10.1084\/jem.20131224"},{"key":"2877_CR100","doi-asserted-by":"publisher","unstructured":"Pouzol L, et al. ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases. FASEB J Off Publ Fed Am Soc Exp Biol. 2021;35(3):e21431. https:\/\/doi.org\/10.1096\/fj.202002465R.","DOI":"10.1096\/fj.202002465R"},{"key":"2877_CR101","doi-asserted-by":"publisher","unstructured":"Pouzol L et al. ACKR3 Antagonism Enhances the Repair of Demyelinated Lesions Through Both Immunomodulatory and Remyelinating Effects, Neurochem. Res. 2024;49(8):2087\u20132104. https:\/\/doi.org\/10.1007\/s11064-024-04173-1.","DOI":"10.1007\/s11064-024-04173-1"},{"key":"2877_CR102","doi-asserted-by":"publisher","unstructured":"Andr\u00e9s-Benito P, et al. Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis. Int J Mol Sci. 2020;21(22). https:\/\/doi.org\/10.3390\/ijms21228680.","DOI":"10.3390\/ijms21228680"},{"key":"2877_CR103","doi-asserted-by":"publisher","unstructured":"Sanfilippo C, Castrogiovanni P, Imbesi R, Nunnari G, Rosa MD. Postsynaptic damage and microglial activation in AD patients could be linked CXCR4\/CXCL12 expression levels. Brain Res. 2020;1749:147127. https:\/\/doi.org\/10.1016\/j.brainres.2020.147127.","DOI":"10.1016\/j.brainres.2020.147127"},{"key":"2877_CR104","doi-asserted-by":"publisher","unstructured":"Puchert M, et al. Astrocytic expression of the CXCL12 receptor, CXCR7\/ACKR3 is a hallmark of the diseased, but not developing CNS. Mol Cell Neurosci. 2017;85:105\u201318. https:\/\/doi.org\/10.1016\/j.mcn.2017.09.001.","DOI":"10.1016\/j.mcn.2017.09.001"},{"key":"2877_CR105","doi-asserted-by":"publisher","unstructured":"Wang Q, et al. Stromal cell-derived factor 1\u03b1 decreases \u03b2-amyloid deposition in Alzheimer\u2019s disease mouse model. Brain Res. 2012;1459:15\u201326. https:\/\/doi.org\/10.1016\/j.brainres.2012.04.011.","DOI":"10.1016\/j.brainres.2012.04.011"},{"key":"2877_CR106","doi-asserted-by":"publisher","unstructured":"Gavriel Y, Rabinovich-Nikitin I, Ezra A, Barbiro B, Solomon B. Subcutaneous Administration of AMD3100 into Mice Models of Alzheimer\u2019s Disease Ameliorated Cognitive Impairment, Reduced Neuroinflammation, and Improved Pathophysiological Markers, J. Alzheimer\u2019s Dis. 2020;78(2):653\u2013671. https:\/\/doi.org\/10.3233\/JAD-200506.","DOI":"10.3233\/JAD-200506"},{"key":"2877_CR107","doi-asserted-by":"publisher","unstructured":"Parachikova A, Cotman CW. Reduced CXCL12\/CXCR4 results in impaired learning and is downregulated in a mouse model of Alzheimer disease., Neurobiol. Dis. 2007;28(2):143\u2013153. https:\/\/doi.org\/10.1016\/j.nbd.2007.07.001.","DOI":"10.1016\/j.nbd.2007.07.001"},{"key":"2877_CR108","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.bbi.2019.09.003","volume":"82","author":"S Das","year":"2019","unstructured":"Das S, Mishra KP, Chanda S, Ganju L, Singh SB. CXCR7: A key neuroprotective molecule against alarmin HMGB1 mediated CNS pathophysiology and subsequent memory impairment. Brain Behav Immun. 2019;82:319\u201337. https:\/\/doi.org\/10.1016\/j.bbi.2019.09.003.","journal-title":"Brain Behav Immun"},{"issue":"5","key":"2877_CR109","doi-asserted-by":"publisher","first-page":"132","DOI":"10.31083\/j.jin2205132","volume":"22","author":"C Cattaneo","year":"2023","unstructured":"Cattaneo C, Jost WH. Pain in Parkinson\u2019s Disease: Pathophysiology, Classification and Treatment. JIN. 2023;22(5):132\u2013null.","journal-title":"JIN"},{"key":"2877_CR110","doi-asserted-by":"publisher","unstructured":"Qu Y, et al. A systematic review and meta-analysis of inflammatory biomarkers in Parkinson\u2019s disease. NPJ Park Dis. 2023;9(1). https:\/\/doi.org\/10.1038\/s41531-023-00449-5.","DOI":"10.1038\/s41531-023-00449-5"},{"key":"2877_CR111","doi-asserted-by":"publisher","unstructured":"Li Y, et al. CXCL12 is involved in \u03b1-synuclein-triggered neuroinflammation of Parkinson\u2019s disease. J Neuroinflammation. 2019;16(1):263. https:\/\/doi.org\/10.1186\/s12974-019-1646-6.","DOI":"10.1186\/s12974-019-1646-6"},{"key":"2877_CR112","doi-asserted-by":"publisher","unstructured":"Gate D et al. Nov., CD4(+) T cells contribute to neurodegeneration in Lewy body dementia., Science. 2021;374(6569):868\u2013874. https:\/\/doi.org\/10.1126\/science.abf7266.","DOI":"10.1126\/science.abf7266"},{"key":"2877_CR113","doi-asserted-by":"publisher","unstructured":"Xu J-T, et al. Effect of stromal cell-derived factor-1\/CXCR4 axis in neural stem cell transplantation for Parkinson\u2019s disease. Neural Regen Res. 2020;15(1):112\u20139. https:\/\/doi.org\/10.4103\/1673-5374.264470.","DOI":"10.4103\/1673-5374.264470"},{"key":"2877_CR114","doi-asserted-by":"publisher","unstructured":"De Gioia R, et al. Neural Stem Cell Transplantation for Neurodegenerative Diseases. Int J Mol Sci. 2020;21(9). https:\/\/doi.org\/10.3390\/ijms21093103.","DOI":"10.3390\/ijms21093103"},{"key":"2877_CR115","doi-asserted-by":"publisher","unstructured":"Zhang J et al. Resveratrol Protects PC12 Cell against 6-OHDA Damage via CXCR4 Signaling Pathway., Evid. Based. Complement. Alternat. Med. 2015;2015:730121. https:\/\/doi.org\/10.1155\/2015\/730121.","DOI":"10.1155\/2015\/730121"},{"key":"2877_CR116","doi-asserted-by":"publisher","first-page":"102587","DOI":"10.1016\/j.pneurobio.2024.102587","volume":"235","author":"V La Cognata","year":"2024","unstructured":"La Cognata V, Morello G, Guarnaccia M, Cavallaro S. The multifaceted role of the CXC chemokines and receptors signaling axes in ALS pathophysiology. Prog Neurobiol. 2024;235:102587. https:\/\/doi.org\/10.1016\/j.pneurobio.2024.102587.","journal-title":"Prog Neurobiol"},{"issue":"1","key":"2877_CR117","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12974-016-0587-6","volume":"13","author":"I Rabinovich-Nikitin","year":"2016","unstructured":"Rabinovich-Nikitin I, Ezra A, Barbiro B, Rabinovich-Toidman P, Solomon B. Chronic administration of AMD3100 increases survival and alleviates pathology in SOD1G93A mice model of ALS. J Neuroinflammation. 2016;13(1):123. https:\/\/doi.org\/10.1186\/s12974-016-0587-6.","journal-title":"J Neuroinflammation"},{"key":"2877_CR118","doi-asserted-by":"publisher","unstructured":"Dapash M, Hou D, Castro B, Lee-Chang C, Lesniak MS. The Interplay between Glioblastoma and Its Microenvironment., Cells. 2021;10(9) https:\/\/doi.org\/10.3390\/cells10092257.","DOI":"10.3390\/cells10092257"},{"issue":"1","key":"2877_CR119","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","volume":"29","author":"K Kohli","year":"2022","unstructured":"Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 2022;29(1):10\u201321. https:\/\/doi.org\/10.1038\/s41417-021-00303-x.","journal-title":"Cancer Gene Ther"},{"key":"2877_CR120","doi-asserted-by":"publisher","unstructured":"Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity. 2021;54(5):859\u201374. https:\/\/doi.org\/10.1016\/j.immuni.2021.01.012.","DOI":"10.1016\/j.immuni.2021.01.012"},{"key":"2877_CR121","doi-asserted-by":"publisher","unstructured":"Isci D, et al. Patient-Oriented Perspective on Chemokine Receptor Expression and Function in Glioma. Cancers (Basel). 2021;14(1). https:\/\/doi.org\/10.3390\/cancers14010130.","DOI":"10.3390\/cancers14010130"},{"key":"2877_CR122","doi-asserted-by":"publisher","unstructured":"D\u2019Uonnolo G, et al. Patient-based multilevel transcriptome exploration highlights relevant chemokines and chemokine receptor axes in glioblastoma. Comput Biol Med. 2024;182:109197. https:\/\/doi.org\/10.1016\/j.compbiomed.2024.109197.","DOI":"10.1016\/j.compbiomed.2024.109197"},{"key":"2877_CR123","doi-asserted-by":"publisher","unstructured":"Smaldone G, et al. Targeting the CXCR4\/CXCL12 Axis in Cancer Therapy: Analysis of Recent Advances in the Development of Potential Anticancer Agents. Molecules. 2025;30(6). https:\/\/doi.org\/10.3390\/molecules30061380.","DOI":"10.3390\/molecules30061380"},{"key":"2877_CR124","doi-asserted-by":"publisher","unstructured":"Stevenson CB et al. Sep., CXCR4 expression is elevated in glioblastoma multiforme and correlates with an increase in intensity and extent of peritumoral T2-weighted magnetic resonance imaging signal abnormalities., Neurosurgery. 2008;63(3):560\u2013570. https:\/\/doi.org\/10.1227\/01.NEU.0000324896.26088.EF.","DOI":"10.1227\/01.NEU.0000324896.26088.EF"},{"key":"2877_CR125","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fncel.2014.00144","volume":"8","author":"R W\u00fcrth","year":"2014","unstructured":"W\u00fcrth R, Bajetto A, Harrison JK, Barbieri F, Florio T. CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment. Front Cell Neurosci. 2014;8:144. https:\/\/doi.org\/10.3389\/fncel.2014.00144.","journal-title":"Front Cell Neurosci"},{"key":"2877_CR126","doi-asserted-by":"publisher","unstructured":"Louis DN et al. Aug., The 2021 WHO Classification of Tumors of the Central Nervous System: a summary., Neuro. Oncol. 2021;23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106.","DOI":"10.1093\/neuonc\/noab106"},{"key":"2877_CR127","doi-asserted-by":"publisher","unstructured":"Schaff LR, Mellinghoff IK. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA. 2023;329(7):574\u201387. https:\/\/doi.org\/10.1001\/jama.2023.0023.","DOI":"10.1001\/jama.2023.0023"},{"key":"2877_CR128","doi-asserted-by":"publisher","unstructured":"Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice., J. Clin. Invest. 2010;120(3):694\u2013705. https:\/\/doi.org\/10.1172\/JCI40283.","DOI":"10.1172\/JCI40283"},{"key":"2877_CR129","doi-asserted-by":"publisher","unstructured":"Alghamri MS et al. Jun., Systemic Delivery of an Adjuvant CXCR4\u2013CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy, ACS Nano. 2022;16(6):8729\u20138750. https:\/\/doi.org\/10.1021\/acsnano.1c07492.","DOI":"10.1021\/acsnano.1c07492"},{"key":"2877_CR130","doi-asserted-by":"publisher","unstructured":"Wu A et al. Jun., Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment., J. Neurooncol. 2019;143(2):241\u2013249. https:\/\/doi.org\/10.1007\/s11060-019-03172-5.","DOI":"10.1007\/s11060-019-03172-5"},{"key":"2877_CR131","doi-asserted-by":"publisher","unstructured":"Goffart N, et al. CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone. Neuro Oncol. 2017;19(1):66\u201377. https:\/\/doi.org\/10.1093\/neuonc\/now136.","DOI":"10.1093\/neuonc\/now136"},{"key":"2877_CR132","doi-asserted-by":"publisher","unstructured":"Wang S, Chen C, Li J, Xu X, Chen W, Li F. The CXCL12\/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1. J Neurol Sci. 2020;414:116837. https:\/\/doi.org\/10.1016\/j.jns.2020.116837.","DOI":"10.1016\/j.jns.2020.116837"},{"key":"2877_CR133","doi-asserted-by":"publisher","unstructured":"Lee EQ, et al. Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. Clin cancer Res Off J Am Assoc Cancer Res. 2018;24:4643\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1025.","DOI":"10.1158\/1078-0432.CCR-18-1025"},{"key":"2877_CR134","doi-asserted-by":"publisher","unstructured":"Thomas RP et al. Dec., Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I\/II Trial using a CXCR4 Inhibitor in Glioblastoma., Clin. cancer Res. an Off. J. Am. Assoc. Cancer Res. 2019;25(23):6948\u20136957. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1421.","DOI":"10.1158\/1078-0432.CCR-19-1421"},{"key":"2877_CR135","doi-asserted-by":"publisher","unstructured":"Allen M, Bjerke M, Edlund H, Nelander S, Westermark B. Origin of the U87MG glioma cell line: Good news and bad news. Sci Transl Med. 2016;8(354):354re3. https:\/\/doi.org\/10.1126\/scitranslmed.aaf6853.","DOI":"10.1126\/scitranslmed.aaf6853"},{"key":"2877_CR136","doi-asserted-by":"publisher","unstructured":"Mercurio L, et al. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. J Exp Clin Cancer Res. 2016;35:55. https:\/\/doi.org\/10.1186\/s13046-016-0326-y.","DOI":"10.1186\/s13046-016-0326-y"},{"key":"2877_CR137","doi-asserted-by":"publisher","unstructured":"D\u2019Alterio C, et al. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1. J Exp Clin Cancer Res. 2019;38(1):432. https:\/\/doi.org\/10.1186\/s13046-019-1420-8.","DOI":"10.1186\/s13046-019-1420-8"},{"issue":"4","key":"2877_CR138","doi-asserted-by":"publisher","first-page":"201083","DOI":"10.1016\/j.omton.2025.201083","volume":"33","author":"D Paolo","year":"2025","unstructured":"Paolo D, et al. An oncolytic herpesvirus expressing a CXCR4 antagonist interferes with glioblastoma cells\u2019 stemness features and migration. Mol Ther Oncol. 2025;33(4):201083. https:\/\/doi.org\/10.1016\/j.omton.2025.201083.","journal-title":"Mol Ther Oncol"},{"issue":"5","key":"2877_CR139","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/bjc.2013.830","volume":"110","author":"MJ Walters","year":"2014","unstructured":"Walters MJ, et al. Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats. Br J Cancer. 2014;110(5):1179\u201388. https:\/\/doi.org\/10.1038\/bjc.2013.830.","journal-title":"Br J Cancer"},{"issue":"6","key":"2877_CR140","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41419-024-06784-6","volume":"15","author":"C-C Liu","year":"2024","unstructured":"Liu C-C, et al. CXCR7 activation evokes the anti-PD-L1 antibody against glioblastoma by remodeling CXCL12-mediated immunity. Cell Death Dis. 2024;15(6):434. https:\/\/doi.org\/10.1038\/s41419-024-06784-6.","journal-title":"Cell Death Dis"},{"key":"2877_CR141","doi-asserted-by":"publisher","unstructured":"Liu S-C et al. Jan., Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats., Neuro. Oncol. 2014;16(1):21-28. https:\/\/doi.org\/10.1093\/neuonc\/not149.","DOI":"10.1093\/neuonc\/not149"},{"issue":"1","key":"2877_CR142","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1038\/s41467-024-48416-9","volume":"15","author":"FA Giordano","year":"2024","unstructured":"Giordano FA, et al. L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I\/II GLORIA trial. Nat Commun. 2024;15(1):4210. https:\/\/doi.org\/10.1038\/s41467-024-48416-9.","journal-title":"Nat Commun"},{"key":"2877_CR143","doi-asserted-by":"publisher","unstructured":"Miao Z et al. Oct., CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature., Proc. Natl. Acad. Sci. U. S. A. 2007;104(40):15735\u201315740. https:\/\/doi.org\/10.1073\/pnas.0610444104.","DOI":"10.1073\/pnas.0610444104"},{"key":"2877_CR144","doi-asserted-by":"publisher","unstructured":"Chung B, et al. Human brain metastatic stroma attracts breast cancer cells via chemokines CXCL16 and CXCL12. NPJ breast cancer. 2017;3(6). https:\/\/doi.org\/10.1038\/s41523-017-0008-8.","DOI":"10.1038\/s41523-017-0008-8"},{"key":"2877_CR145","doi-asserted-by":"publisher","unstructured":"Cavallaro S. CXCR4\/CXCL12 in non-small-cell lung cancer metastasis to the brain., Int. J. Mol. Sci. 2013;14(1):1713\u20131727. https:\/\/doi.org\/10.3390\/ijms14011713.","DOI":"10.3390\/ijms14011713"},{"key":"2877_CR146","doi-asserted-by":"publisher","unstructured":"Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1\/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases., Am. J. Respir. Crit. Care Med. 2003;197(12):1676\u20131686. https:\/\/doi.org\/10.1164\/rccm.200301-071OC","DOI":"10.1164\/rccm.200301-071OC"},{"issue":"12","key":"2877_CR147","first-page":"5259","volume":"9","author":"H Li","year":"2017","unstructured":"Li H, et al. AMD3100 inhibits brain-specific metastasis in lung cancer via suppressing the SDF-1\/CXCR4 axis and protecting blood-brain barrier. Am J Transl Res. 2017;9(12):5259\u201374.","journal-title":"Am J Transl Res"},{"issue":"12","key":"2877_CR148","doi-asserted-by":"publisher","first-page":"100470","DOI":"10.1016\/j.xcrm.2021.100470","volume":"2","author":"SA Rajakumar","year":"2021","unstructured":"Rajakumar SA, Grandal I, Minden MD, Hitzler JK, Guidos CJ, Danska JS. Targeted blockade of immune mechanisms inhibit B precursor acute lymphoblastic leukemia cell invasion of the central nervous system. Cell Rep Med. 2021;2(12):100470. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100470.","journal-title":"Cell Rep Med"},{"key":"2877_CR149","doi-asserted-by":"publisher","unstructured":"Jost TR, et al. Role of CXCR4-mediated bone marrow colonization in CNS infiltration by T cell acute lymphoblastic leukemia. J Leukoc Biol. 2016;99:1077\u201387. https:\/\/doi.org\/10.1189\/jlb.5MA0915-394R.","DOI":"10.1189\/jlb.5MA0915-394R"},{"key":"2877_CR150","doi-asserted-by":"publisher","unstructured":"Jonart LM, Ostergaard J, Brooks A, Fitzpatrick G, Chen L, Gordon PM. CXCR4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance. Br J Haematol. 2023;201(3):459\u201369. https:\/\/doi.org\/10.1111\/bjh.18607.","DOI":"10.1111\/bjh.18607"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02877-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02877-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02877-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:46:20Z","timestamp":1780620380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02877-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":150,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2877"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02877-1","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"335"}}